Prader-Willi Syndrome Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036

Market Overview:

The Prader-Willi syndrome market reached a value of USD 682.6 Million in 2025. Looking forward, IMARC Group expects the 7MM to reach USD 1,390.3 Million by 2036, exhibiting a growth rate (CAGR) of 6.70% during 2026-2036.

The Prader-Willi syndrome market has been comprehensively analyzed in IMARC's new report titled "Prader-Willi Syndrome Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036". Prader-Willi syndrome refers to a rare genetic disorder that occurs due to the loss of specific genes on chromosome 15, which are typically inherited from the father. This condition is characterized by a distinctive pattern of symptoms, such as a chronic feeling of hunger, obesity, intellectual disabilities, behavioral problems, etc. Numerous other common indications of the disease include underdeveloped sex organs, poor growth and physical development, stubbornness, short stature, cognitive impairment, delayed motor development, speech problems, temper tantrums, reduced hormone production, lazy eye, etc. Individuals suffering from Prader-Willi syndrome may also experience psychiatric conditions like anxiety and mood disorders. The diagnosis of this ailment is mainly based on evaluating the patient's reported symptoms, medical history, and a generic blood test. The healthcare provider may also perform DNA-based methylation testing to identify abnormalities or changes in the chromosome that indicate the syndrome. Additionally, various diagnostic procedures, such as fluorescence in-situ hybridization and chromosomal microarray analysis, are utilized to rule out other possible causes of the underlying symptoms.

The rising cases of genetic disorders on account of an error in one or more genes in a particular region of chromosome 15 are primarily driving the Prader-Willi syndrome market. Furthermore, the widespread adoption of growth hormone therapy, which promotes development, increases muscle mass, reduces body fat, etc., for managing the growth hormone deficiency associated with the ailment is also propelling the market growth. In addition to this, the inflating utilization of behavioral and psychiatric interventions for addressing a patient's emotional challenges and boosting social skills is further acting as another significant growth-inducing factor. Moreover, the escalating demand for lifestyle modifications, such as the consumption of a well-balanced, calorie-restricted diet, on account of its several associated benefits, including maintaining a healthy weight and minimizing the likelihood of other complications related to the ailment, is also creating a positive outlook for the market. Apart from this, the emerging popularity of intranasal selective oxytocin receptors, since they can aid in appetite regulation and improve social functioning, reduce repetitive behaviors, as well as address hyperphagia in patients, is expected to drive the Prader-Willi syndrome market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Prader-Willi syndrome market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Prader-Willi syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Prader-Willi syndrome market in any manner.

Recent Developments:

• In February 2026 , Aardvark Therapeutics announced a voluntary pause of its Phase III HERO trial evaluating ARD-101 for hyperphagia in patients with Prader-Willi syndrome. The decision was based on reversible cardiac safety observations at supratherapeutic doses identified during a healthy volunteer study, prompting the company to halt enrollment and dosing while conducting a comprehensive data review to determine next steps, reflecting ongoing safety challenges in late-stage PWS drug development.
• In November 2025, the US FDA has delayed its decision on Soleno Therapeutics investigational therapy for children with Prader-Willi syndrome. The new decision date for Soleno’s DCCR (diazoxide choline) extended-release tablets is set for March 2025 – three months longer than the previous FDA extended review period. The delay comes after the FDA classified recent responses from Soleno as a “major amendment” to its new drug application (NDA), requiring additional time to review. However, the agency has not raised concerns about the drug’s safety, efficacy, or manufacturing.
• In September 2025 , Acadia Pharmaceuticals announced the discontinuation of its investigational drug intranasal carbetocin (ACP-101) for Prader-Willi syndrome after failure in a Phase III COMPASS PWS trial. The study did not demonstrate statistically significant improvement over placebo in hyperphagia scores or secondary endpoints, highlighting the ongoing challenges in developing effective therapies for appetite dysregulation in PWS.
• In July 2025, ConSynance Therapeutics announced that its investigational medication CSTI-500 had been given Rare Pediatric Disease Designation (RPDD) by the US FDA for the treatment of Prader-Willi Syndrome in children and adolescents.
• In April 2025, Soleno Therapeutics reported that diazoxide choline had been granted Breakthrough Therapy Designation by the US FDA for the treatment of adults and children aged 4 and up with genetically proven Prader-Willi syndrome and hyperphagia. The designation represents the Agency's decision that, based on an evaluation of preliminary data from the Phase 3 clinical development program, diazoxide choline may outperform existing treatments on a clinically relevant endpoint(s).
• In March 2025 , Soleno Therapeutics announced that the U.S. Food and Drug Administration approved VYKAT XR (diazoxide choline extended-release) for the treatment of hyperphagia in adults and children aged 4 years and older with Prader-Willi syndrome. This approval marks the first-ever pharmacological treatment specifically targeting hyperphagia in PWS, addressing a critical unmet need associated with severe, persistent hunger and related complications.

Key Highlights:

• The prevalence of Prader-Willi syndrome is one in every 20,000 to 30,000 births.
• Prader-Willi syndrome affects around 400,000 people worldwide, 20,000 of whom live in the United States.
• It remains the most common hereditary cause of life-threatening obesity.
• The reported prevalence rates for Prader-Willi syndrome range from one per 8,000 people in rural Sweden to one per 16,000 people in western Japan.
• The annual mortality rate of PWS ranges between 1% and 4%.

Drugs:

GENOTROPIN (somatropin) is a prescription drug licensed in the United States for children with Prader-Willi syndrome. GENOTROPIN is injected just beneath the skin and is available in a variety of devices to meet specific dose requirements. GENOTROPIN is similar to the body's natural growth hormone and has a well-established safety profile.

ACP-101 is an investigational drug in the form of an intranasal formulation of carbetocin being developed for the treatment of hyperphagia in Prader-Willi syndrome (PWS). For the treatment of Prader-Willi syndrome specifically, a central nervous system disorder, an intranasal formulation of carbetocin was developed, which provides direct delivery of the drug to the brain, greatly reducing systemic exposure and the potential for side effects. ACP-101 has been granted Orphan Drug, Fast Track, and Rare Pediatric Disease designations by the FDA.

Time Period of the Study

• Base Year: 2025
• Historical Period: 2020-2025
• Market Forecast: 2026-2036
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Prader-Willi syndrome market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Prader-Willi syndrome market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Prader-Willi syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Prader-Willi syndrome market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2025 and how are they expected to perform till 2036?
• What was the country-wise size of the Prader-Willi syndrome market across the seven major markets in 2025 and what will it look like in 2036?
• What is the growth rate of the Prader-Willi syndrome market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2020-2036) of Prader-Willi syndrome across the seven major markets?
• What is the number of prevalent cases (2020-2036) of Prader-Willi syndrome by age across the seven major markets?
• What is the number of prevalent cases (2020-2036) of Prader-Willi syndrome by gender across the seven major markets?
• What is the number of prevalent cases (2020-2036) of Prader-Willi syndrome by type across the seven major markets?
• How many patients are diagnosed (2020-2036) with Prader-Willi syndrome across the seven major markets?
• What is the size of the Prader-Willi syndrome patient pool (2020-2025) across the seven major markets?
• What would be the forecasted patient pool (2026-2036) across the seven major markets?
• What are the key factors driving the epidemiological trend of Prader-Willi syndrome?
• What will be the growth rate of patients across the seven major markets?
   

Prader-Willi Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Prader-Willi syndrome drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Prader-Willi syndrome market?
• What are the key regulatory events related to the Prader-Willi syndrome market?
• What is the structure of clinical trial landscape by status related to the Prader-Willi syndrome market?
• What is the structure of clinical trial landscape by phase related to the Prader-Willi syndrome market?
• What is the structure of clinical trial landscape by route of administration related to the Prader-Willi syndrome market?